Drugs / GFH276
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07846358 | Nov 2026 → Dec 2027 expected | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07678593 | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07198321 | Sep 2025 → Sep 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07784374 | Aug 2026 → Aug 2028 expected | malignant pancreatic neoplasm | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Genfleet Therapeutics (Shanghai) Inc. | Results AACR: 劲方泛RAS抑制剂GFH276临床前实验起效剂量低于海外同靶点产品，与多款标准治疗联用均显著协同增效 genfleet.com ↗
壁报显示GFH276在多种RAS突变的动物模型中，以低至1/3剂量即可达到或超越RMC-6236的抑瘤效果。 |
| 2026-03-20 | Genfleet Therapeutics (Shanghai) Inc. | Results 聚焦RAS赛道前沿分子形态：劲方医药三款创新大、小分子临床前数据将登陆2026年AACR年会 genfleet.com ↗
临床前研究在多种 KRAS 突变模型中证实，GFH276单药口服即可对非小细胞肺癌、结直肠癌、胰腺癌、胆管癌及子宫内膜癌等瘤种产生显著且剂量依赖性的抗肿瘤效果；与西妥昔单抗、PD-1单抗等药物联用后会产生显著的协同增效作用，展示单药及联用疗法的广阔治疗前景。 |
| 2025-04-28 | Genfleet Therapeutics (Shanghai) Inc. | Results AACR现场：劲方泛RAS抑制剂GFH276临床前研究显示广谱、低剂量起效的抑瘤活性，及克服多重耐药的治疗潜力 genfleet.com ↗
在多类KRAS突变肿瘤模型中，GFH276显示了相较于海外同类产品的更低起效剂量和更佳药代动力学特征。 |
| 2025-04-09 | Genfleet Therapeutics (Shanghai) Inc. | Results AACR预告：劲方医药三款大、小分子产品临床前研究将登陆2025 AACR年会壁报 genfleet.com ↗
GFH276在激酶选择性和安全相关靶点测试中展现了良好的安全性及靶向特异性；并在多种机理的KRAS G12C抑制剂耐药细胞系中，均保持强效活性并显示多重抗耐药潜力。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Genfleet Therapeutics (Shanghai) Inc. | AACR: 劲方泛RAS抑制剂GFH276临床前实验起效剂量低于海外同靶点产品，与多款标准治疗联用均显著协同增效 genfleet.com ↗ |
| 2026-03-20 | Genfleet Therapeutics (Shanghai) Inc. | 聚焦RAS赛道前沿分子形态：劲方医药三款创新大、小分子临床前数据将登陆2026年AACR年会 genfleet.com ↗ |
| 2025-04-28 | Genfleet Therapeutics (Shanghai) Inc. | AACR现场：劲方泛RAS抑制剂GFH276临床前研究显示广谱、低剂量起效的抑瘤活性，及克服多重耐药的治疗潜力 genfleet.com ↗ |
| 2025-04-09 | Genfleet Therapeutics (Shanghai) Inc. | AACR预告：劲方医药三款大、小分子产品临床前研究将登陆2025 AACR年会壁报 genfleet.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07784374 ↗ |
| Route | Oral | “administered at the assigned dose level, orally” NCT07198321 ↗ |